What is Fractyl Health, Inc.'s (GUTS) StockRank?

MoatMap's StockRank for Fractyl Health, Inc. (GUTS) is 5/100, with a Strong Sell signal. This is a composite score combining Quality (21), Value (24), and Momentum (30) factor ranks across MoatMap's 20,000+ stock universe.

Does Fractyl Health, Inc. have an economic moat?

Fractyl Health, Inc. (GUTS) has a Quality factor score of 21/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Fractyl Health, Inc. a buy, hold, or sell?

MoatMap's current signal for Fractyl Health, Inc. (GUTS) is Strong Sell, based on a StockRank of 5/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Fractyl Health, Inc. in?

Fractyl Health, Inc. (GUTS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

GUTS

STRONG SELL

Fractyl Health, Inc. · Healthcare · United States · $130M · Avg Vol: $2M/d

StockRank

P/E (TTM)

—

ROE

-778.3%

D/E

2.8x

Dividend %

—

Director Trades · 180d

+$127.4K →

Buybacks · 180d

None in 180d →

COMPANY DESCRIPTION

Fractyl Health, Inc. is a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, including type 2 diabetes and obesity. The company's competitive moat is centered on its proprietary Revita system, a duodenal mucosal resurfacing procedure, and its Rejuva gene therapy platform. It operates as an innovative niche player aiming to transform the treatment paradigm for chronic metabolic conditions.

PRICE (1Y)+15.1%

SMA 50SMA 200

$0.87

RSI (14)

50.2

52W High

$2.44

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

-93.9%5.7

ROE

-778.3%0.8

GP/Assets

—N/A

Op. Margin

0.0%40.3

FCF/Assets

-41.7%5.6

Piotroski

238.9

Int. Cover

—N/A

D/E Ratio

2.84x3.7

Current Ratio

4.28x66.1

Value

P/E (TTM)

—N/A

EV/EBITDA

-1.5x25.0

P/FCF

—N/A

P/B

6.1x21.1

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

36%N/A

RS 6M

-71%N/A

SMA 50/200

0.67xN/A

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+59%58.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$130M

P/E (Forward)

-1.5x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GUTS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
GUTS	Fractyl Health, Inc.(you)	$130M	5	STRONG SELL
2592.HK	Cloudbreak Pharma Inc.	$125M	5	STRONG SELL
ALDX	Aldeyra Therapeutics, Inc.	$128M	3	STRONG SELL
CUE	Cue Biopharma, Inc.	$126M	6	STRONG SELL
PEPG	PepGen Inc.	$134M	8	STRONG SELL
COYA	Coya Therapeutics, Inc.	$123M	8	STRONG SELL
GNLX	Genelux Corporation	$135M	1	STRONG SELL
NTHI	NeOnc Technologies Holdings, Inc.	$133M	1	STRONG SELL
CBUS	Cibus, Inc.	$108M	4	STRONG SELL
0HIY.L	Atara Biotherapeutics, Inc.	$161M	6	STRONG SELL

Peer medians: ROE -22.7% · P/E 25.2x · Gross margin 44.3%

Fractyl Health, Inc. (GUTS) — Stock Score Summary

Fractyl Health, Inc. (GUTS) has a MoatMap StockRank of 5/100 based on Quality (21/100), Value (24/100), and Momentum (30/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$0.87
Market Cap	$130M
P/E (Forward)	-1.52
Price/Book	6.11
Return on Equity	-778.3%
Return on Invested Capital	-93.9%
Debt/Equity	284.50
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-51M

Fractyl Health, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Fractyl Health, Inc.’s (GUTS) StockRank?: MoatMap’s StockRank for Fractyl Health, Inc. (GUTS) is 5/100, with a Strong Sell signal. It is a composite of Quality (21), Value (24), and Momentum (30) factor ranks across MoatMap’s 20,000+ stock universe.
Does Fractyl Health, Inc. have an economic moat?: Fractyl Health, Inc. (GUTS) has a Quality factor score of 21/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Fractyl Health, Inc. a buy, hold, or sell?: MoatMap’s current signal for Fractyl Health, Inc. (GUTS) is Strong Sell, based on a StockRank of 5/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Fractyl Health, Inc. in?: Fractyl Health, Inc. (GUTS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).